You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

Select Your Country or Region


Interim report January – September 2011

Interim report January – September 2011

Reporting period January – September

  • Orders received declined by 4.6% to SEK 15,579 M (16,331), and grew organically by 3.8%
  • Net sales declined by 6.6% to SEK 14,500 M (15,531), and grew organically by 1.7%
  • Profit before tax amounted to SEK 1,913 M (1,912)
  • Net profit increased by 2.2% to SEK 1,416 M (1,386)
  • Earnings per share increased by 2.0% to SEK 5.92 (5.80)

Reporting period July – September

  • Orders received grew organically during the quarter by 7.1%
  • Acquisition of Atrium Medical in the U.S. strengthens Getinge in the cardiovascular market
  • Earnings outlook remains favourable for 2011

Third quarter 2011

Orders received                  

The Group’s orders received continued to improve and grew organically by a strong 7.1% during the quarter. All business areas reported favourable order growth.
Medical Systems’ orders received grew organically by 8.2% and of the business area’s divisions reported improvements.
Extended Care bolstered its orders received organically by 4.6% and the corresponding increase for Infection Control was 7.8%.
From a geographic perspective and for the Group as a whole, the trend for orders received proceeded according to plan with continued highly robust growth in markets outside North America and Western Europe.
Orders received in North America were at a solid level, while the trend in Europe was positive albeit more modest.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander
20 October 2011 at 10:00 a.m.

Sweden: +46 8 505 597 72 (always use the area code)
UK: + 44 207 108 6303

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.